Incyte and Merck work together on NSCLC trial; later expanded to include additional cancers
Executive Summary
Incyte Corp. and Merck & Co. Inc. will conduct a Phase I/II trial on a combination of Incyte's INCB24360 with Merck's MK3475 for metastatic and recurrent non-small cell lung cancer and other advanced tumors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice